石药集团(01093.HK) 宣布,集团开发的化药1类新药SYH2059片已获得美国食品药品监督管理局(FDA)批准,可以在美国开展临床试验,获批的临床适应症为间质性肺疾病。该产品已于上月取得国家药监局批准,可在中国开展临床试验。该产品由石药集团小分子药物创新设计平台研发,是一款全新的、具有完全自主知识产权的高活性与高选择性的环核苷酸磷酸二酯酶4B(PDE4B)抑制剂。集团指,临床前研究表明该产品...
Source Link石药集团(01093.HK) 宣布,集团开发的化药1类新药SYH2059片已获得美国食品药品监督管理局(FDA)批准,可以在美国开展临床试验,获批的临床适应症为间质性肺疾病。该产品已于上月取得国家药监局批准,可在中国开展临床试验。该产品由石药集团小分子药物创新设计平台研发,是一款全新的、具有完全自主知识产权的高活性与高选择性的环核苷酸磷酸二酯酶4B(PDE4B)抑制剂。集团指,临床前研究表明该产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.